One To Watch
Allogenetics
Company Overview
Allogenetics is working on a different logic for transplant medicine. Rather than suppressing the recipient's immune system, it modifies the organ itself, so it is not recognized as foreign by the host immune system.
Lead candidate ALG-115 is a one-time ex vivo treatment applied in the window between organ procurement and implantation. The company's stated goal is to improve graft survival and patient quality of life.
Headquarters and Global Presence
Allogenetics GmbH is headquartered in Hanover, Germany. The company operates as a private, preclinical-stage entity focused on transplantation immunology research and development. Its current footprint is concentrated in Germany, consistent with its early development stage.
Founding and History
The company was co-founded by Prof. Dr. Rainer Blasczyk, who served as its first Chief Medical Officer before transitioning to the role of Clinical Advisor in July 2026, and Prof. Dr. Constanca Figueiredo, who serves as Chief Scientific Officer.
Oliver Ernst, PhD, leads the company as Chief Executive Officer.
Therapy Areas and Focus
Allogenetics works across transplantation medicine, gene therapy, and immunology, addressing a clinical problem that remains poorly served.
Lifelong immunosuppression after solid organ transplantation carries serious long-term consequences: elevated infection risk, malignancy, and progressive renal toxicity.
The company's approach targets that burden at the source, engineering the graft to reduce the immunological provocation it presents to the recipient. ALG-115 is initially focused on lung transplantation.
Technology Platforms and Modalities
The core platform is ex vivo gene therapy: genetic modification of a donor organ during the procurement-to-implantation interval, before the recipient ever encounters the graft.
The mechanism involves a calibrated downregulation of MHC class I and class II antigen presentation on cell surfaces, making the organ less recognizable as foreign to the recipient's T cells.
Because the intervention is localized to the organ, it does not compromise the patient's systemic immune defenses. The organ-agnostic design of the platform supports the company's expansion ambitions beyond lung transplantation.
Key Pipeline and Programs
ALG-115 is Allogenetics' lead and sole disclosed program. It is an ex vivo gene therapy applied directly to the donor organ, targeting MHC class I and II antigen presentation pathways to reduce graft immunogenicity.
The indication is initially lung transplantation, a setting with high rejection rates, a heavy immunosuppression burden, and acute unmet need. The company plans to extend ALG-115's application to other solid organs in a subsequent development phase, using the platform's organ-agnostic design.
ALG-115 is advancing toward clinical evaluation and remains at the preclinical stage. No trial registration numbers are publicly available at this time.
The one-time, organ-level administration profile is the commercially and clinically distinctive feature. It removes the compliance burden of chronic immunosuppression and concentrates the intervention at a single, controlled procedural moment.
Recent Developments
Allogenetics appointed Jeroen Rovers, MD, PhD, as Chief Medical Officer on July 21, 2026. The hire signals that the company is preparing ALG-115 for clinical-stage execution.
Rovers succeeds co-founder Prof. Dr. Rainer Blasczyk, who steps back to a Clinical Advisor role. Recruiting a dedicated chief medical officer is a meaningful operational milestone for a preclinical company moving toward first-in-human studies.
Key Personnel
Oliver Ernst, PhD, serves as Chief Executive Officer. Dr. Frank Schnieders serves as Chief Development Officer, and Prof. Dr. Constanca Figueiredo is a company co-founder and Chief Scientific Officer.
Jeroen Rovers, MD, PhD, was appointed Chief Medical Officer on July 21, 2026. Prof. Dr. Rainer Blasczyk, a company co-founder, supports the leadership team as Strategic Clinical Advisor following his transition from the CMO role.
Strategic Partnerships
Allogenetics closed a €3.4 million seed round in September 2024, jointly led by NBank Capital and CARMA FUND I. No licensing or co-development partnerships have been publicly announced.
FAQ Section
Conventional transplant medicine suppresses the recipient's immune system systemically to prevent rejection. That approach trades one problem, graft loss, for another: infection, cancer and kidney damage accumulating over decades.
Allogenetics' thesis is that localizing the intervention to the organ, before it ever enters the recipient, removes the trade-off. If ALG-115 works as intended, the recipient retains full immune competence while the graft avoids immune attack.
MHC class I and II molecules are the cell-surface proteins that flag a donor organ as foreign to the recipient's T cells. They are the primary trigger for acute and chronic rejection.
By genetically downregulating both molecules ex vivo, Allogenetics aims to reduce the immunological signal the graft emits without eliminating it entirely, preserving a degree of immune surveillance.
A calibrated reduction rather than total ablation is designed to balance tolerance induction against the risk of removing protection against infection or malignancy within the graft itself.
Most experimental tolerance strategies work systemically. Regulatory T cell therapies, costimulation blockade and mixed chimerism protocols all have to be given to the recipient before or around transplantation, which adds complexity and recipient-side risk.
ALG-115 is applied to the organ during procurement, in a controlled ex vivo window, keeping the intervention entirely outside the patient until transplant. The one-time administration profile also removes the compliance burden that undermines long-term immunosuppression regimens.
ALG-115 is at the preclinical stage and advancing toward clinical evaluation. No Phase I trial has yet been registered publicly.
Lung transplantation is the lead indication, a deliberate choice given that lung recipients carry among the highest immunosuppression burdens and worst long-term outcomes of any solid organ group.
The company's platform can also be applied to other transplant organs in the future, once the lung program establishes proof-of-concept.
The disclosed pipeline centers on ALG-115 as a platform asset rather than an indication-specific drug. The company's organ-agnostic framing means the same ex vivo gene therapy approach is intended to extend across solid organ types.
That makes Allogenetics a platform company rather than a single-indication bet. All programs remain preclinical, and the breadth of the pipeline depends on establishing clinical proof-of-concept in lung first.
Allogenetics is a private, preclinical-stage company working toward first-in-human studies with ALG-115. The July 2026 appointment of a chief medical officer suggests it is actively building the clinical infrastructure for an IND or CTA submission.
Key near-term milestones will be IND/CTA filing, regulatory alignment on trial design for lung transplantation, and the initiation of a Phase I safety study.
The company is at an early stage, with most of the decisive events still ahead. Key catalysts and risks include:
- Preclinical-to-clinical translation: whether MHC downregulation in animal models reproduces in human organ biology and surgical contexts.
- Regulatory pathway: the ex vivo gene therapy classification raises novel questions for EMA review, and there is little precedent for trial design in first-in-human organ gene therapy.
- Clinical trial initiation: announcement of a Phase I start in lung transplantation would be the most significant near-term catalyst.
- Financing: the seed round closed in September 2024, and whether the company can reach clinical proof-of-concept without a further raise is a key unknown.
- Platform expansion: progress toward other solid organ transplantation studies would validate the organ-agnostic thesis and substantially expand the addressable market.
Today's issue
| Headless Content Management with Blaze